Sano Genetics: against COVID-19 Company
Entity: Sano Genetics
Category: COVID Research
Description: Sano Genetics is a personalised medicine research platform with data privacy and transparency at its core. Sano Genetics is a user-centric genetic data marketplace that connects individuals directly to the research world. It act as ethical brokers to facilitate a direct connection between you and research institutions.
Project: The COVID-19 Host Genetics Initiative
Summary: Sano Genetics is Partner of the global project 'COVID-19 Host Genetics Initiative'. Important findings from this project are shared openly so the worldwide scientific community can work together on COVID-19 solutions. The name of the work is "Sano at-home testing and digital data collection for COVID19 human genetics research".
Location: Cambridge, United Kingdom
Research question: Their primary research aim is to help identify genetic variants that are linked to COVID19 severity and/or risk of infection. They intend to share summary statistics and data with the COVID19hg consortium to enable meta analysis of their data in combination with other consortium members. Pending funding availability, they will use their at-home digital phenotyping platform to collect longitudinal data from severely and mildly affected COVID19 patients and healthy volunteers who may later be affected by COVID19 in order to assess genetic factors related to recovery, re-infection, and comorbidities associated with risk/severity.
Study design: They intend to recruit cases who are under 50, have tested positive for COVID19, have been hospitalised, and have no severe pre-existing conditions. They will collect saliva and, pending grant funding, blood to perform genotyping arrays initially and next-generation sequencing pending grant funding. They will contribute data to EGA and summary statistics to the COVID19hg consortium for meta-analysis.
Study Type: Prospective (n=150)
Genetic analysis: WES, GWAS
Investigators: Dr Patrick Short
+ Investors:
Daniel Murrell
Ramesh Haridas
Paul Forster
University of Cambridge Enterprise
Will Neale
Seedcamp
